All Blogs

acute-ocular-pain-treatment-landscape

Jan 16, 2023

New Technologies Conquering Drug Delivery Obstacles in Acute Ocular Pain Treatment Landscape


behcets-syndrome-treatment-market

Jan 13, 2023

Off-label Therapies Dominating the Behcet’s Syndrome Treatment Market


MedTech News and Updates for Vivos, Arthrex, Chindex, Glaukos, Zimmer Biomet

Jan 12, 2023

Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial


Digital Health Major Transformative Trends and Market Dynamics

Jan 11, 2023

Digital Health: Insights Into the Key Transformative Trends & Evolving Market Dynamics


Latest Pharma News and Updates for Ipsen, Chiesi, Takeda, ACELYRIN, Lantern Pharma

Jan 10, 2023

Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL


eosinophilic-esophagitis-treatment-outlook

Jan 09, 2023

Is it the Dawn of Biologics in the Eosinophilic Esophagitis Treatment Landscape?


osteomyelitis-treatment-outlook

Jan 06, 2023

Osteomyelitis Treatment Market: Evaluating the New Line of Therapies in the Therapeutics Space


MedTech News and Updates for Inspira, Burning Rock, Verana, liberDi, Innova

Jan 05, 2023

Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System


Ocular Implants Market Trends, Growth, Key Companies, and Emerging Products

Jan 04, 2023

Insights Into the Evolving Landscape of the Ocular Implants Market


Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB

Jan 03, 2023

Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi